Femasys Inc (FEMY) stock

FEMYNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/3072% below fair value

$1.42+0.02 (+1.43%)

Close on Nov 13, 2026Market cap $11.89MP/E –Yield –

Femasys price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Femasys's price to sales ratio was 2.0× on Nov 11, 2026, against 23.2× a year earlier. Over the last 5 years it ranged from 1.8× to 38.1×, with a median of 14.3×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	2.0×	−11.2
2025	Dec 31, 2025	13.2×	−6.2
2024	Dec 31, 2024	19.4×	+5.1
2023	Dec 29, 2023	14.3×	+5.6
2022	Dec 30, 2022	8.7×	−29.5
2021	Dec 31, 2021	38.1×	–

Where these numbers come from

Parsed from the XBRL in Femasys's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-20 reverse split on Jun 8, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is FEMY.

Compare: FEMY vs IVF · FEMY vs OSRH · FEMY vs SINT · FEMY vs INBS · FEMY vs ICCM

Revenue growth-4.2% · median 36.5%

Gross margin59.9% · median 50.9%

Operating margin-929.9% · median -287.8%

Net margin-614.7% · median -269.3%

Company	Revenue	Growth
IVF	$7.53M	–
INBS	$4.50M	+36.5%
SINT	$3.31M	+160.8%
FEMY	$1.97M	-4.2%
OSRH	$1.71M	-50.4%
ICCM	–	–

Company

Next earnings (est.): Mar 30, 2027, after close
Exchange: Nasdaq
Industry: Surgical & Medical Instruments & Apparatus
Fiscal year ends: December 31
Employees: 51
Held by institutions: 24.7%
Auditor: KPMG LLP
SEC CIK: 1339005

Advertisement
300 × 250

See a number that looks wrong?